Macrogenics Inc MGNX
Macrogenics Inc (Nasdaq: MGNX) is an oncology drug developer. Its lead program, MGC026 (B7-H3 TOP1i ADC) / MGC028 (ADAM9 TOP1i ADC), is in Phase 1 for advanced solid tumors. Its next catalyst on record is MGC028: Initial clinical data report (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: MGC028 — Initial clinical data report (H2 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| vobramitamab duocarmazine | discontinued internal development | antibody | Phase 2 |
| MGC026 | B7-H3-expressing solid tumors (Phase 1 dose escalation fully enrolled; dose expansion ongoing) | antibody | Phase 1 |
| MGC028 | advanced solid tumors (ADAM9) | antibody | Phase 1 |
| lorigerlimab (PD-1 x CTLA-4 DART) | not stated in extract (LORIKEET and LINNET studies referenced) | antibody | Phase 1 |
| MGD024 (CD123 x CD3 DART, Gilead option) | hematologic malignancies (CD123) | antibody | Phase 1 |
| MGC030 (ADC, undisclosed target) | solid tumors | antibody | Pre-clinical |
Recent results and decisions
- Oct 23, 2026positive MGC026 demonstrated durable responses with 29% confirmed ORR in patients with advanced solid tumors receiving ≥6 mg/kg dose.
Among 17 response-evaluable patients representing 10 different tumor types who received MGC026 at doses of at least 6 mg/kg in dose escalation, the confirmed objective response rate was 29% (5/17), and the disease control rate was 65% (11/17).
Filing - Apr 8, 2026hold lifted FDA removed the partial clinical hold on the Phase 2 LINNET study of lorigerlimab; enrollment to resume under a revised protocol with added risk-mitigation measures.
FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study
Filing - Feb 23, 2026clinical hold FDA placed a partial clinical hold on Phase 2 LINNET after Grade 4 events in four patients (incl. one Grade 5); no new enrollment, 41 patients dosed.
the U. S. Food and Drug Administration (FDA) has placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab, an investigational, bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with gynecologic cancers.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.